Published in JAMA on February 23, 2000
Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med (2004) 3.12
Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids (2007) 2.56
Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol (2001) 1.87
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol (2009) 1.71
Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrinol (2006) 1.54
Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback. Arch Womens Ment Health (2012) 1.45
Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology (2015) 1.45
Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage (2010) 1.45
Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther (2010) 1.39
Alzheimer's disease and mild cognitive impairment. Neurol Clin (2007) 1.39
Estrogens and age-related memory decline in rodents: what have we learned and where do we go from here? Horm Behav (2008) 1.39
Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci U S A (2001) 1.34
Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev (2009) 1.33
Genetic aspects of Alzheimer disease. Genet Med (2008) 1.26
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.25
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev (2008) 1.21
Higher levels of estradiol replacement correlate with better spatial memory in surgically menopausal young and middle-aged rats. Neurobiol Learn Mem (2008) 1.18
Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis (2010) 1.16
Sex differences in autoimmune diseases. Biol Sex Differ (2011) 1.16
Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci (2011) 1.10
Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol (2013) 1.10
Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS One (2009) 1.09
Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause (2013) 1.08
Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol (2014) 1.08
Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol (2009) 1.07
Sex hormones, aging, and Alzheimer's disease. Front Biosci (Elite Ed) (2012) 1.06
Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci (2005) 1.06
Estrogen neuroprotection and the critical period hypothesis. Front Neuroendocrinol (2011) 1.03
Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev (2012) 1.03
Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric (2012) 1.00
Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology (2006) 0.98
Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? Oxid Med Cell Longev (2014) 0.97
Clinical trial design issues in mild to moderate Alzheimer disease. Cogn Behav Neurol (2008) 0.97
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance. Brain Res (2010) 0.96
Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J Alzheimers Dis (2011) 0.95
Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol (2012) 0.95
The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res (2007) 0.95
Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv Pharmacol (2012) 0.93
Cognitive dysfunction with aging and the role of inflammation. Ther Adv Chronic Dis (2011) 0.92
Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Cognitive changes after menopause: influence of estrogen. Clin Obstet Gynecol (2008) 0.91
Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol (2014) 0.91
Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol (2013) 0.89
Neuroprotective effects of estrogen therapy for cognitive and neurobiological profiles of monkey models of menopause. Am J Primatol (2009) 0.88
Estrogen and hippocampal plasticity in rodent models. J Alzheimers Dis (2008) 0.88
Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 0.88
The potential for estrogens in preventing Alzheimer's disease and vascular dementia. Ther Adv Neurol Disord (2009) 0.87
Estrogens, Neuroinflammation, and Neurodegeneration. Endocr Rev (2016) 0.87
Alzheimer's disease. Dialogues Clin Neurosci (2000) 0.86
Alzheimer's disease in man and transgenic mice: females at higher risk. Am J Pathol (2001) 0.86
Estrogen and neuroprotection: from clinical observations to molecular mechanisms. Dialogues Clin Neurosci (2002) 0.86
Estrogen as a treatment for Alzheimer disease. JAMA (2000) 0.85
Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: an evidence-based approach. Prim Care Companion CNS Disord (2013) 0.85
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem (2013) 0.84
The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset. Int Rev Psychiatry (2013) 0.84
Activation of the annexin A1 pathway underlies the protective effects exerted by estrogen in polymorphonuclear leukocytes. Arterioscler Thromb Vasc Biol (2011) 0.83
Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimers Dement (2010) 0.83
Sex and Gender Differences in Central Nervous System-Related Disorders. Neurosci J (2016) 0.82
Donepezil plus estradiol treatment enhances learning and delay-dependent memory performance by young ovariectomized rats with partial loss of septal cholinergic neurons. Horm Behav (2011) 0.82
Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm (Vienna) (2006) 0.82
Estrogens, episodic memory, and Alzheimer's disease: a critical update. Semin Reprod Med (2009) 0.82
Transcriptome meta-analysis reveals a central role for sex steroids in the degeneration of hippocampal neurons in Alzheimer's disease. BMC Syst Biol (2013) 0.81
Estrogen-cholinergic interactions: Implications for cognitive aging. Horm Behav (2015) 0.80
Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies. Mol Neurobiol (2014) 0.80
Estrogen modifies arousal but not memory for emotional events in older women. Neurobiol Aging (2007) 0.79
Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.79
Therapeutic approaches to age-associated neurocognitive disorders. Dialogues Clin Neurosci (2001) 0.79
A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. Alzheimers Res Ther (2014) 0.78
[Role of hormone-replacement therapy for prevention of coronary artery disease in women]. Z Kardiol (2005) 0.78
Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia. CNS Drugs (2016) 0.78
Aging and substitutive hormonal therapy influence in regional and subcellular distribution of ERα in female rat brain. Age (Dordr) (2012) 0.78
Effects of an herbal medication containing bee products on menopausal symptoms and cardiovascular risk markers: results of a pilot open-uncontrolled trial. MedGenMed (2004) 0.77
Hormones as "difference makers" in cognitive and socioemotional aging processes. Front Psychol (2015) 0.77
Locus Coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease. Neurobiol Stress (2015) 0.77
Long-term consequences of estrogens administered in midlife on female cognitive aging. Horm Behav (2015) 0.77
Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies? Cell Mol Neurobiol (2015) 0.77
Stroke, dementia, and drug delivery. Br J Clin Pharmacol (2004) 0.77
Sex and gonadal hormones in mouse models of Alzheimer's disease: what is relevant to the human condition? Biol Sex Differ (2012) 0.77
Estrogen and Alzheimer disease: plausible theory, negative clinical trial. JAMA (2000) 0.76
Postmenopausal syndrome. Indian J Psychiatry (2015) 0.76
Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence. Clin Interv Aging (2008) 0.76
Hormones and dementia - a comparative study of hormonal impairment in post-menopausal women, with and without dementia. Neuropsychiatr Dis Treat (2006) 0.76
Actions and interactions of estradiol and glucocorticoids in cognition and the brain: Implications for aging women. Neurosci Biobehav Rev (2015) 0.76
Interviews With Two Women's Health Experts On the Use of Estrogen Therapies. P T (2012) 0.75
Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology (2017) 0.75
Estrogen deficiency is associated with hippocampal morphological remodeling of early postmenopausal mice. Oncotarget (2017) 0.75
Treatment of cognitive impairment in Alzheimer's disease. Dialogues Clin Neurosci (2003) 0.75
Message about hormone replacement therapy is unclear. BMJ (2002) 0.75
Estrogen in cardiovascular disease during systemic lupus erythematosus. Clin Ther (2014) 0.75
Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimers Dement (N Y) (2015) 0.75
Regional and Gender Study of Neuronal Density in Brain during Aging and in Alzheimer's Disease. Front Aging Neurosci (2016) 0.75
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimers Res Ther (2017) 0.75
Estrogen as a treatment for Alzheimer disease. JAMA (2000) 0.75
A cell-biased effect of estrogen in prion infection. J Virol (2013) 0.75
Enhanced Neuroactivation during Working Memory Task in Postmenopausal Women Receiving Hormone Therapy: A Coordinate-Based Meta-Analysis. Front Hum Neurosci (2015) 0.75
The sequence of the human genome. Science (2001) 101.55
A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc (1975) 21.45
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Changing provider behavior: an overview of systematic reviews of interventions. Med Care (2001) 17.89
Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med (1990) 16.54
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 5.94
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med (1992) 5.93
Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients. Health Technol Assess (2001) 5.84
Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging (1997) 5.66
Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest (1999) 5.30
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77
Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol (1992) 4.63
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci (1993) 4.60
A simplified acute physiology score for ICU patients. Crit Care Med (1984) 4.55
Boolean formalization of genetic control circuits. J Theor Biol (1973) 4.54
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol (1989) 4.21
Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci U S A (1997) 4.13
Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 4.06
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci (1997) 3.61
Mutations in two Ku homologs define a DNA end-joining repair pathway in Saccharomyces cerevisiae. Mol Cell Biol (1996) 3.57
The Multicenter AIDS Cohort Study: retention after 9 1/2 years. Am J Epidemiol (1995) 3.54
Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology (1997) 3.53
In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res (1991) 3.45
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci (2000) 3.40
Genetics and physiology of defective lysogeny in K12 (lambda): studies of early mutants. Virology (1966) 3.39
Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology (1995) 3.37
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology (1996) 3.23
Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res (1996) 3.18
Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17
The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A (2002) 3.11
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology (2003) 3.07
Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol (1992) 3.04
Treatment of Alzheimer's disease. N Engl J Med (1999) 3.03
Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol (1999) 3.03
Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry (1996) 2.99
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
A validation study of the Dementia Questionnaire. Arch Neurol (1994) 2.89
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology (1991) 2.77
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology (2000) 2.76
Measurement of free electrophoretic mobility and retardation coefficient of protein-sodium dodecyl sulfate complexes by gel electrophoresis. A method to validate molecular weight estimates. J Biol Chem (1972) 2.73
Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J Neurosci (1988) 2.73
Distribution of N-methyl-D-aspartate-sensitive L-[3H]glutamate-binding sites in rat brain. J Neurosci (1985) 2.66
A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann Intern Med (1996) 2.66
Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. Arch Ophthalmol (1999) 2.65
Thousandfold change in resistivity in magnetoresistive la-ca-mn-o films. Science (1994) 2.64
Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A (1993) 2.62
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev (2006) 2.59
Thyroxine should be tried in clinically hypothyroid but biochemically euthyroid patients. BMJ (1997) 2.58
Prevalence of primary glaucoma in an urban south Indian population. Indian J Ophthalmol (1998) 2.58
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol (1996) 2.50
Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol (1989) 2.49
Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology (1984) 2.48
Hydrogen-poor superluminous stellar explosions. Nature (2011) 2.48
Brain dysmorphology in individuals with severe prenatal alcohol exposure. Dev Med Child Neurol (2001) 2.44
Synaptic proteins. Characterization of tubulin and actin and identification of a distinct postsynaptic density polypeptide. J Cell Biol (1978) 2.44
Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol (1997) 2.43
Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J Neurol Neurosurg Psychiatry (1994) 2.40
Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol (2000) 2.37
Quitting cigarettes completely or switching to smokeless tobacco: do US data replicate the Swedish results? Tob Control (2009) 2.36
Motor vehicle crashes in dementia of the Alzheimer type. Ann Neurol (1988) 2.36
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer (2003) 2.31
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry (1998) 2.30
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
Cognitive test performance among nondemented elderly African Americans and whites. Neurology (1998) 2.28
Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res (1990) 2.26
Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem (1995) 2.24
In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology (2007) 2.24
Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J Am Geriatr Soc (1996) 2.23
Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res (1984) 2.21
Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature (1989) 2.17
Assessing patient dependence in Alzheimer's disease. J Gerontol (1994) 2.16
Detection and characterization of novel rotavirus strains in the United States. J Clin Microbiol (1998) 2.16
In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med (1997) 2.15
Survival and growth of hippocampal neurons in defined medium at low density: advantages of a sandwich culture technique or low oxygen. Brain Res (1989) 2.12
Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med (2000) 2.12